CDK11A/CDK11B Antibody

What are the main differences between CDK11A and CDK11B, and how should researchers choose antibodies that target one or both proteins?

CDK11A and CDK11B are encoded by two duplicated genes that are 99% identical in protein sequence. CDK11A (also known as CDC2L2) and CDK11B (also known as CDC2L1) both have multiple isoforms including p110, p58, and p46. The p110 isoforms are involved in pre-mRNA splicing and transcription, while the p58 isoforms play roles in cell cycle regulation at the G2/M transition .

When choosing an antibody:

• For studies requiring discrimination between CDK11A and CDK11B, use isoform-specific antibodies targeting unique epitopes

• For general CDK11 function studies, antibodies that recognize both proteins (like those targeting the conserved C-terminal kinase domain) are appropriate

• Consider the application requirements: some antibodies work better for WB versus IHC or IF

Research consideration: Both genes encode nearly identical serine/threonine protein kinases (PITSLREB and PITSLREA respectively), so complete discrimination can be challenging . Confirm specificity through validation experiments in your experimental system.

What are the optimal experimental conditions for using CDK11A/CDK11B antibodies in immunohistochemistry?

For optimal immunohistochemistry with CDK11A/CDK11B antibodies:

Sample preparation and antigen retrieval:

• Use formalin-fixed, paraffin-embedded (FFPE) sections

• Perform heat-induced epitope retrieval using citrate buffer (pH 6.0) or Target Retrieval Solution

• Deparaffinize in xylene (15 minutes), rehydrate through graded alcohols (100% to 50%)

Blocking and antibody incubation:

• Block with peroxidase blocking reagent (5 minutes), followed by serum, avidin, and biotin blocking reagents (15 minutes each)

• Use primary CDK11 antibody at optimal dilution (typically 1:50-1:200) and incubate overnight at 4°C

• For secondary antibody, use biotinylated antibody (1:200 dilution) for 1 hour

• Develop with DAB substrate for visualization

Controls and validation:

• Include negative controls (omit primary antibody)

• Use known positive samples (HeLa or cancer tissues) to benchmark staining

Evaluation metrics: Grade nuclear staining patterns on a 0-5+ scale as follows: 0 (no staining), 1+ (<10% cells positive), 2+ (10-25% positive), 3+ (26-50% positive), 4+ (51-75% positive), 5+ (>75% positive) .

How can CDK11A/CDK11B antibodies be optimized for Western blot applications?

For optimal Western blot results with CDK11A/CDK11B antibodies:

Sample preparation:

• Use 6% SDS-PAGE gels for optimal separation of the large CDK11 proteins (~93-110 kDa)

• Load approximately 40 μg of protein lysate per lane

• Include positive control lysates (HeLa, HepG2, or other validated cells)

Antibody conditions:

• Use primary antibody at 1:500-1:2000 dilution

• For CDK11B antibodies, recommended dilution is typically 1:750

• Incubate membrane with primary antibody overnight at 4°C for best results

• Secondary antibody dilution approximately 1:8000

• Exposure time around 1 minute is typically sufficient

Expected results:

• Full-length CDK11 p110 isoform should be detected at approximately 110 kDa

• The p58 isoform (if present in G2/M phase cells) at approximately 58 kDa

• The p46 caspase-cleaved product may be detected in apoptotic samples

Validation approach: Compare bands across multiple cell lines (e.g., HeLa, HepG2, Lovo cells) and human cancer tissue lysates to confirm specificity and expected molecular weight .

What are the key considerations when using CDK11A/CDK11B antibodies for cancer research applications?

When using CDK11A/CDK11B antibodies in cancer research:

Expression patterns:

• CDK11 expression is upregulated in human ovarian cancer tissues and associated with malignant progression

• Metastatic and recurrent tumors show significantly higher CDK11 expression compared to matched primary tumors

• CDK11B shows increased expression in breast cancer cells, while CDK11A typically shows no significant differences in expression compared to normal breast tissue

Methodological approaches:

• Use tissue microarrays (TMAs) with matched primary, metastatic, and recurrent tumor tissues for comparative analysis

• Evaluate nuclear staining patterns quantitatively (percentage of positive cells)

• Employ siRNA or shRNA knockdown of CDK11 to assess functional effects in cancer cells

• Consider combination studies with chemotherapeutic agents (e.g., paclitaxel)

Technical considerations:

• 100% of triple-negative breast cancer (TNBC) tumors stain positive for CDK11 with high nuclear intensity compared to normal tissue

• Use immunofluorescence in cultured cancer cells to assess subcellular localization before and after treatments

• Consider analyzing both protein and mRNA levels to comprehensively assess CDK11 expression

Emerging therapeutic relevance: CDK11 has emerged as a potential therapeutic target in numerous cancers, including liposarcoma, osteosarcoma, multiple myeloma, breast cancer, and ovarian cancer .

How does SAP30BP function as an activator of CDK11, and how can antibodies help study this interaction?

SAP30BP functions as a critical CDK11 activator through several mechanisms:

Mechanism of activation:

• SAP30BP forms a tight complex with CDK11 and cyclins L1/L2

• SAP30BP ensures the stability of cyclins L1/L2, which are essential for CDK11 activation

• SAP30BP facilitates the assembly of cyclins L1/L2 with CDK11

• Acute degradation of SAP30BP mirrors CDK11 in causing widespread pre-mRNA splicing defects

Experimental approaches using antibodies:

• Co-immunoprecipitation (co-IP): Use CDK11 antibodies to pull down the complex and detect SAP30BP, or vice versa

• Western blotting: Monitor protein levels of CDK11, SAP30BP, and cyclins L1/L2 after manipulating expression of either protein

• Immunofluorescence: Examine co-localization of CDK11 and SAP30BP in cellular compartments

Research findings:

• In double KI HeLa cells expressing Flag-FKBP12-CDK11 and HA-SAP30BP, SAP30BP and CDK11 efficiently precipitate each other

• Cyclins L1/L2 and CKIIα are co-precipitated with both SAP30BP and CDK11

• SAP30BP interacts with CDK11 and cyclins L1/L2 independent of RNA

• CDK11 degradation does not reduce either cyclin L protein levels or their interactions with SAP30BP

This interaction represents a novel regulatory mechanism for CDK11 activation that could be targeted therapeutically in CDK11-dependent cancers .

What are the best methods for validating the specificity of CDK11A/CDK11B antibodies in experimental applications?

To validate CDK11A/CDK11B antibody specificity:

Genetic approaches:

• siRNA/shRNA knockdown: Validate antibody specificity by confirming reduced signal after CDK11 knockdown

• CRISPR/Cas9 knockout: Generate complete knockout cells as negative controls

• Overexpression: Transfect cells with tagged CDK11 constructs and confirm co-detection with tag-specific antibodies

Biochemical validation:

• Western blot: Confirm single bands of expected molecular weight (91-110 kDa for p110, ~58 kDa for p58)

• Multiple antibodies: Use antibodies targeting different epitopes of CDK11 to verify consistent results

• Peptide competition: Pre-incubate antibody with immunizing peptide to block specific binding

Controls and standards:

• Positive controls: Use cell lines with known CDK11 expression (HeLa, HepG2, Lovo cells)

• Negative controls: Include secondary antibody-only controls

• Cross-reactivity assessment: Test on samples from different species to confirm predicted reactivity

Validation across applications:

• For multi-application antibodies, verify specificity in each application (WB, IHC, IP, IF)

• For IHC validation: Compare staining patterns with literature reports and confirm nuclear localization

• For IP validation: Confirm pull-down of interacting partners like cyclins L1/L2

Example validation data: Antibody specificity can be visualized by western blot showing specific bands in multiple cell lines (HeLa, HepG2, Lovo cells, human cancer tissues) at the predicted molecular weight of 93 kDa .

How can CDK11A/CDK11B antibodies be used to study pre-mRNA splicing mechanisms?

CDK11 plays a critical role in pre-mRNA splicing, and antibodies can be used to investigate this function:

Experimental approaches:

• RNAi-coupled splicing analysis: Use CDK11 antibodies to verify knockdown efficiency before examining splicing patterns using RNA-seq

• Acute degradation systems: In cells with dTAG-CDK11 systems, monitor splicing defects following induced CDK11 degradation

• Phosphorylation studies: Use phospho-specific antibodies to examine CDK11-mediated phosphorylation of splicing factors like SFRS7

Key findings from recent research:

• Acute degradation of CDK11 results in 7,896 intron retention (IR) events at 2 hours post-degradation

• CDK11 and SAP30BP regulate common splicing events with strong correlation (Spearman correlation coefficients 0.77-0.89)

• CDK11-regulated introns are relatively short and harbor stronger 5′ss and 3′ss

• Early retained introns tend to be more 3′ biased

Methodological considerations:

• Use tcRNA-seq analysis to profile splicing defects globally

• Compare splicing profiles between CDK11 knockdown and inhibitor treatment (e.g., OTS964)

• Analyze both early and late effects following CDK11 manipulation to distinguish direct vs. indirect effects

Technical readouts:

• Monitor intron retention events

• Analyze alternative splicing patterns

• Examine recruitment of splicing factors to pre-mRNA

This approach reveals CDK11's essential role in ensuring efficient pre-mRNA splicing across the transcriptome .

What are the structural and functional differences between the CDK11 p110 and p58 isoforms, and how can researchers distinguish them using antibodies?

The p110 and p58 isoforms of CDK11 have distinct structures and functions:

Structural differences:

• p110 isoforms: Full-length proteins containing N-terminal domains, central RE (Arg/Glu) domain, poly-E (Glu) domain, and C-terminal kinase domain

• p58 isoforms: Shorter proteins translated from an internal ribosome entry site, containing primarily the C-terminal kinase domain

Functional differences:

• p110 isoforms: Ubiquitously expressed throughout the cell cycle; involved in pre-mRNA splicing and transcription by phosphorylating splicing proteins like SFRS7

• p58 isoforms: Expressed only during the G2/M transition; involved in centrosome maturation, bipolar spindle formation, and centriole duplication

• p58 may act as a negative regulator of normal cell cycle progression

Distinguishing isoforms using antibodies:

• Epitope selection: Use antibodies targeting the N-terminal region to detect only p110 isoforms

• C-terminal antibodies: Will detect both p110 and p58 isoforms

• Molecular weight discrimination: p110 at ~110 kDa, p58 at ~58 kDa on western blots

Experimental considerations:

• Cell synchronization: p58 is only produced during a narrow window at G2/M transition, making it difficult to detect in unsynchronized cells

• Cyclins: p110 isoforms primarily interact with cyclins L1/L2, while p58 has been reported to bind cyclin D3

• Subcellular localization: Use immunofluorescence to detect different compartmentalization patterns

Existing antibody options: Several commercially available antibodies can detect both isoforms (e.g., Cell Signaling's PITSLRE/CDK11 D88B3 Rabbit mAb) , while others are designed to target specific isoforms or domains .

What role does CDK11 play in autophagy, and how can antibodies help elucidate this function?

CDK11 has been identified as a modulator of autophagy:

Key findings on CDK11's role in autophagy:

• Knockdown of CDK11 (both CDK11A and CDK11B) causes a significant increase in GFP-LC3 puncta, indicating accumulation of autophagosomes

• This autophagy modulation has been observed in both Drosophila S2R+ cells and human cell lines (HeLa and MDA-MB-231)

• CDK11 knockdown initially enhances LC3-II protein levels in the presence of lysosomal inhibitors (E64d/Pepstatin A), indicating autophagy induction

• At later time points, combination of CDK11 knockdown with lysosomal inhibitors shows limited effect, suggesting impaired autophagosomal turnover

• p62 protein levels decrease following CDK11 knockdown, potentially due to reduced p62 mRNA levels

Experimental approaches using antibodies:

• Western blotting: Monitor autophagy markers (LC3-I to LC3-II conversion, p62 levels) after CDK11 knockdown

• Immunofluorescence: Track autophagosome formation using LC3 antibodies in CDK11-depleted cells

• Co-immunoprecipitation: Identify potential interactions between CDK11 and autophagy regulators

Methodological considerations:

• Use siRNAs targeting both CDK11A and CDK11B to fully examine the role of CDK11

• Include lysosomal inhibitors (E64d/Pepstatin A) to distinguish between autophagy induction and impaired autophagosomal turnover

• Examine both early and late time points to capture the dynamic effects of CDK11 loss on autophagy

• Consider measuring both protein and mRNA levels of autophagy markers

These findings suggest CDK11 may play dual roles in autophagy: initially, loss of CDK11 induces autophagy, but ultimately leads to impaired autophagosomal turnover .

How can researchers use CDK11 inhibitor OTS964 in conjunction with CDK11 antibodies to study kinase function?

The OTS964 inhibitor and CDK11 antibodies can be used complementarily to study CDK11 kinase function:

Properties of OTS964:

• Shows specificity for CDK11 (10× more potent than against CDK7, with no apparent binding to other CDKs)

• Binds to the CDK11 kinase domain and induces an active-like conformation despite the absence of cyclin

• A single amino acid mutation (Gly223Ser) in CDK11 confers resistance to OTS964

Experimental strategies combining OTS964 and antibodies:

• Target validation:

  • Use CDK11 antibodies to confirm expression levels before OTS964 treatment

  • Compare OTS964 effects with CDK11 knockdown phenotypes using antibodies to verify target specificity

• Structural studies:

  • Use antibodies to immunoprecipitate CDK11-OTS964 complexes for structural analysis

  • Perform immunoblotting to detect conformational changes induced by OTS964 binding

• Resistance mechanisms:

  • Generate OTS964-resistant cell lines (e.g., with Gly223Ser mutation)

  • Use antibodies to confirm expression of mutant CDK11 and analyze altered binding partners

• Global effects analysis:

  • Apply CDK11 antibodies to examine changes in CDK11 localization after OTS964 treatment

  • Immunoprecipitate CDK11 from OTS964-treated cells to identify altered protein interactions

Key research findings:

• Treatment with OTS964 shows similar splicing defects to those observed after CDK11 degradation

• OTS964 binding to the CDK11 kinase domain has been characterized by a 2.6 Å crystal structure

• Specific amino acids likely contribute to OTS964 specificity for CDK11

This combined approach allows researchers to distinguish between kinase-dependent and scaffold functions of CDK11 and identify specific kinase substrates relevant to CDK11's cellular roles.

What methodological approaches can be used to study CDK11's role in cancer cell proliferation using specific antibodies?

To investigate CDK11's role in cancer cell proliferation using antibodies:

RNA interference approaches:

• siRNA transfection: Verify CDK11 knockdown efficiency using western blotting with CDK11 antibodies

• shRNA lentiviral transduction: Monitor stable knockdown using immunofluorescence and western blotting

• Analyze cell proliferation following knockdown using assays like CellTiter 96® AQueous One Solution Cell Cytotoxicity Assay

Tissue analysis:

• Perform immunohistochemistry on tissue microarrays containing matched primary, metastatic, and recurrent tumor samples

• Grade CDK11 nuclear staining (0-5+ scale) and correlate with clinical parameters

• Compare CDK11 expression between tumor and adjacent normal tissues

Cell death and cell cycle analysis:

• Use CDK11 antibodies to confirm knockdown before measuring apoptosis markers

• Combine with Ki-67 staining to assess proliferation rates

• Analyze cell cycle distribution after CDK11 manipulation

Drug sensitivity studies:

• Pre-treat cells with CDK11 inhibitors (e.g., OTS964) or CDK11 knockdown

• Evaluate enhanced sensitivity to chemotherapeutics (e.g., paclitaxel)

• Confirm CDK11 modulation using antibodies before drug treatment

Experimental data:

• RNAi-mediated CDK11 silencing decreases cell proliferation and induces apoptosis in ovarian cancer cells

• CDK11 knockdown enhances the cytotoxic effect of paclitaxel

• Systemic delivery of nanoparticle-formulated siRNA targeting CDK11 inhibits tumor growth in xenograft models

• 100% of triple-negative breast cancer tumors show high nuclear CDK11 staining compared to normal tissue

These approaches reveal CDK11 as a potential therapeutic target across multiple cancer types due to its essential role in cancer cell proliferation .

What are the technical challenges in developing phospho-specific CDK11 antibodies, and how can they be used in research?

Developing and using phospho-specific CDK11 antibodies presents several technical challenges:

Challenges in development:

• Sequence homology issues:

  • CDK11A and CDK11B share 99% sequence identity, making it difficult to generate isoform-specific phospho-antibodies

  • High conservation among CDK family members requires careful epitope selection to avoid cross-reactivity

• Multiple phosphorylation sites:

  • CDK11 contains numerous potential phosphorylation sites with context-dependent activation

  • Identifying functionally relevant phosphorylation sites requires extensive characterization

• Validation complexity:

  • Requires both phosphatase treatment controls and phospho-mimetic/phospho-dead mutants

  • Phosphorylation may be transient or cell cycle-dependent, requiring precise timing for detection

Research applications for phospho-CDK11 antibodies:

• Kinase activity monitoring:

  • Track CDK11 activation status in response to cellular stimuli or drug treatments

  • Correlate phosphorylation with CDK11 kinase activity against substrates

• Cell cycle regulation studies:

  • Monitor CDK11 phosphorylation throughout cell cycle progression

  • Examine differential phosphorylation between p110 and p58 isoforms

• Cancer research applications:

  • Analyze phospho-CDK11 levels in tumor samples versus normal tissues

  • Determine if phosphorylation status correlates with tumor aggression or treatment response

• Drug development:

  • Evaluate efficacy of CDK11 inhibitors by monitoring target engagement through reduced phosphorylation

  • Screen for compounds that specifically prevent CDK11 phosphorylation

Methodological approaches:

• Use phosphatase inhibitors in sample preparation to preserve phosphorylation status

• Combine with immunoprecipitation to enrich for CDK11 before phospho-detection

• Consider using multiple antibodies targeting different phosphorylation sites to create a comprehensive activation profile

While challenging to develop, phospho-specific CDK11 antibodies would provide valuable tools for understanding CDK11 regulation in normal and disease states.

How can researchers optimize immunofluorescence protocols for studying CDK11 subcellular localization?

For optimal immunofluorescence detection of CDK11 subcellular localization:

Sample preparation:

• Seed 3×10^3 cells in 8-well glass chamber slides for adherent cell lines

• Allow 24 hours for cell attachment before experimental treatments

• For knockdown studies, transfect with CDK11 siRNA and continue incubation for 72 hours

Fixation and permeabilization:

• Rinse cells briefly with PBS (3 times)

• Fix with 2% paraformaldehyde for 15 minutes at room temperature

• Permeabilize with ice-cold absolute methanol for 10 minutes at -20°C

• Block with blocking buffer (5% goat serum, 0.3% Triton X-100 in PBS) for 1 hour at room temperature

Antibody incubation:

• Dilute CDK11 primary antibodies at 1:50-1:200 in antibody dilution buffer (1% BSA, 0.3% Triton X-100 in PBS)

• For co-localization studies, include antibodies against known interactors (e.g., β-actin at 1:1000)

• Incubate with primary antibodies overnight at 4°C

• Use appropriate fluorophore-conjugated secondary antibodies (typically 1:500 dilution)

Imaging and analysis:

• Expected subcellular localization: primarily nuclear for p110 isoforms, with some cytoplasmic distribution

• Use confocal microscopy for detailed subcellular localization

• Include DAPI nuclear counterstain for reference

• For quantitative analysis, measure nuclear vs. cytoplasmic signal intensity ratios

Special considerations:

• CDK11's interaction with splicing factors creates a speckled nuclear pattern in some cell types

• During mitosis, CDK11 (particularly p58) localizes to centrosomes and mitotic spindles

• SAP30BP co-localization can provide insights into functional complexes

Controls:

• Include siRNA-treated cells to confirm antibody specificity

• Use cells at different cell cycle stages to observe dynamic localization changes

This approach allows for detailed visualization of CDK11 subcellular compartmentalization and dynamic changes in response to experimental conditions.

What are the best experimental approaches for studying the interaction between CDK11 and its cyclin partners?

To study interactions between CDK11 and its cyclin partners:

Co-immunoprecipitation approaches:

• Perform immunoprecipitation with CDK11 antibodies under normal salt conditions (150 mM)

• Analyze co-precipitated cyclins L1/L2 by western blotting

• Include RNase treatment to confirm RNA-independent interactions

• To study cell cycle-specific interactions, synchronize cells before immunoprecipitation

Recombinant protein interaction studies:

• Use purified recombinant proteins (GST-CDK11, MBP-cyclin L1/L2, His-SAP30BP) in pull-down assays

• Add auxiliary factors like SAP30BP to examine enhanced interaction

• Quantify interaction strength by comparing band intensities with/without facilitating factors

Kinase activity assays:

• Immunoprecipitate CDK11-cyclin complexes and measure kinase activity toward substrates

• Compare activities of different cyclin-CDK11 combinations (cyclin L1 vs. L2, cyclin D3 with p58)

• Assess how auxiliary factors like SAP30BP affect kinase activity

Stability analysis:

• Monitor cyclin L1/L2 protein levels after CDK11 or SAP30BP knockdown/degradation

• Assess half-life of cyclins with/without CDK11 or SAP30BP

• Measure mRNA levels to distinguish transcriptional vs. post-transcriptional effects

Research findings:

• CDK11 forms tight complexes with cyclins L1/L2 and SAP30BP

• SAP30BP is required for protein stability of cyclins L1/L2

• SAP30BP enhances the interaction between GST-CDK11 and MBP-cyclin L1/L2 in vitro

• CDK11 degradation doesn't reduce cyclin L protein levels or their interactions with SAP30BP

• Different cyclins may associate with specific CDK11 isoforms (cyclin L with p110, cyclin D3 with p58)

These approaches provide comprehensive insights into the formation, regulation, and function of CDK11-cyclin complexes.

What considerations should be taken when using CDK11A/CDK11B antibodies for cross-species applications?

When using CDK11A/CDK11B antibodies across different species:

Sequence conservation analysis:

• CDK11 is highly conserved across mammals, but sequence variations exist between more distant species

• Human CDK11 shares significant homology with mouse CDK11, making many antibodies cross-reactive

• Some commercial antibodies are verified for both human and mouse reactivity

• Certain antibodies also react with rat, chicken, cow, and pig CDK11

Validation approaches for cross-species applications:

• Western blotting: Compare band patterns between species using positive control lysates

• Peptide competition: Ensure the blocking peptide works across species

• Include appropriate positive controls from each species being tested

• Sequence alignment: Compare the immunogen sequence with the target species CDK11 sequence

Optimization considerations:

• Dilution adjustments: May need different dilutions for optimal results in different species

• Blocking conditions: Species-specific serum may reduce background in some applications

• Fixation protocols: May require modification for tissues from different species

• Detection systems: Consider species-specific secondary antibodies

Cross-reactivity data:

• Many CDK11 antibodies show reactivity with human and mouse samples

• Some antibodies have broader reactivity including rat, chicken, cow, and pig

• Reactivity predictions are often based on sequence homology and require experimental validation

Species-specific isoform considerations:

• Humans have two CDK11 genes (CDK11A and CDK11B), while mice have one gene

• Expression patterns and regulation may differ between species despite sequence conservation